APP transgenic mice: the effect of active and passive immunotherapy in cognitive tasks.
Various immunotherapy strategies for APP transgenic mice have emerged in recent years. Specifically, active immunization with beta-amyloid (A beta) or passive immunization with anti-A beta-antibodies in APP transgenic mice has appeared most promising. Recent studies have shown that treatment of APP transgenic mice either with A beta(40/42) or A beta-specific antibodies can have beneficial effects in cognitive tasks. Active as well as passive immunization have been shown to affect spatial, non-spatial, emotional and object-related learning and memory. Such effects can be observed when treatments are applied prophylactically (before apparent A beta pathology) or therapeutically (after the development of A beta pathology) in APP transgenic mice. This review focuses on such cognitive outcomes of different active and passive immunization strategies in APP transgenic mice.
Röskam
Stephan
S
Department of Neurology, Research Group for Neurological Therapeutics, Biomedical Research Centre, Philipps-University Marburg, Hans-Meerwein-Strasse, 35043 Marburg, Germany.
Neff
Frauke
F
Schwarting
Rainer
R
Bacher
Michael
M
Dodel
Richard
R
D000544:Alzheimer Disease / Q000628:therapy*; D016229:Amyloid beta-Peptides / Q000235:genetics / Q000276:immunology; D016564:Amyloid beta-Protein Precursor / Q000235:genetics*; D000818:Animals; D003072:Cognition Disorders / Q000628:therapy*; D006801:Humans; D007116:Immunization, Passive / Q000379:methods*; D016233:Immunotherapy, Active / Q000379:methods*; D051379:Mice; D008822:Mice, Transgenic; D009483:Neuropsychological Tests; D058255:Protease Nexins; D011956:Receptors, Cell Surface / Q000235:genetics*
C545487:APP protein, human; D016229:Amyloid beta-Peptides; D016564:Amyloid beta-Protein Precursor; D058255:Protease Nexins; D011956:Receptors, Cell Surface